arrow_back Back to App

Drug Price Negotiation: Small-Molecule Drug Period Extended.

This bill aims to extend the period during which pharmaceutical companies can negotiate prices for small-molecule drugs with the government. This change could affect the availability and pricing of certain medications, potentially delaying price reductions for patients.
Key points
The drug price negotiation period for small-molecule drugs will be extended from 7 to 11 years.
This change seeks to equalize negotiation periods across different drug types, potentially impacting pharmaceutical innovation and market competition.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_HR_7174
Sponsor: Rep. Murphy, Gregory F. [R-NC-3]
Process start date: 2024-01-31
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_HR_7174.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2024-01-31.

What are the main provisions?

Key points include:

  • The drug price negotiation period for small-molecule drugs will be extended from 7 to 11 years.
  • This change seeks to equalize negotiation periods across different drug types, potentially impacting pharmaceutical innovation and market competition.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Murphy, Gregory F. [R-NC-3].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-25.

CATEGORIES

Health